Literature DB >> 23561469

Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Yair Herishanu1, Ben-Zion Katz, Andrew Lipsky, Adrian Wiestner.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature monoclonal B cells in peripheral blood, bone marrow, spleen, and lymph nodes. The trafficking, survival, and proliferation of CLL cells is tightly regulated by the surrounding tissue microenvironment and is mediated by antigenic stimulation, close interaction with various accessory cells and exposure to different cytokines, chemokines, and extracellular matrix components. In the last decade there have been major advances in the understanding of the reciprocal interactions between CLL cells and the various microenvironmental compartments. This article discusses the role of the microenvironment in the context of efforts to develop novel therapeutics that target the biology of CLL. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23561469      PMCID: PMC3660068          DOI: 10.1016/j.hoc.2013.01.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  229 in total

1.  N-linked glycosylation selectively regulates autonomous precursor BCR function.

Authors:  Rudolf Ubelhart; Martina P Bach; Cathrin Eschbach; Thomas Wossning; Michael Reth; Hassan Jumaa
Journal:  Nat Immunol       Date:  2010-07-11       Impact factor: 25.606

2.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

3.  Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.

Authors:  Angélique Biancotto; Pradeep K Dagur; John C Fuchs; Adrian Wiestner; C Bruce Bagwell; J Philip McCoy
Journal:  Mod Pathol       Date:  2011-11-18       Impact factor: 7.842

4.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.

Authors:  M F Romano; A Lamberti; P Tassone; F Alfinito; S Costantini; F Chiurazzi; T Defrance; P Bonelli; F Tuccillo; M C Turco; S Venuta
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

6.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia.

Authors:  G Pizzolo; M Chilosi; A Ambrosetti; G Semenzato; L Fiore-Donati; G Perona
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

9.  Immunoarchitecture of the "pseudofollicles" of well-differentiated (small) lymphocytic lymphoma: a comparison with true follicles.

Authors:  H Ratech; K Sheibani; B N Nathwani; H Rappaport
Journal:  Hum Pathol       Date:  1988-01       Impact factor: 3.466

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  48 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 3.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

4.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

5.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

6.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

7.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

8.  Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia.

Authors:  Basile Stamatopoulos; Michaël Van Damme; Emerence Crompot; Barbara Dessars; Hakim El Housni; Philippe Mineur; Nathalie Meuleman; Dominique Bron; Laurence Lagneaux
Journal:  Mol Med       Date:  2015-01-09       Impact factor: 6.354

9.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

10.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.